Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press163210.17650/1726-9776-2023-19-1-17-24DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиThe role of obesity in patients with renal cell carcinomaРоль ожирения у больных почечно-клеточным ракомhttps://orcid.org/0000-0003-1671-369XKravtsovI. B.КравцовИ. Б.
Russian Federation

Igor B. Kravtsov.

86 Profsoyuznaya St., Moscow 117997

Кравцов Игорь Борисович – кандидат медицинских наук, научный сотрудник, заведующий отделом реализации программ ОМС.

117997 Москва, ул. Профсоюзная, 86

ibkravtsov@rncrr.ruhttps://orcid.org/0000-0002-1641-6452SolodkyV. A.СолодкийВ. А.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

Солодкий Владимир Алексеевич – доктор медицинских наук, профессор, академик РАН, директор.

117997 Москва, ул. Профсоюзная, 86

director@rncrr.ruhttps://orcid.org/0000-0002-2905-7735PavlovA. Yu.ПавловА. Ю.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

Павлов Андрей Юрьевич – доктор медицинских наук, профессор, заместитель директора по научно-лечебной работе.

117997 Москва, ул. Профсоюзная, 86

aupavlov@rncrr.ruhttps://orcid.org/0000-0001-5789-375XDzidzariaA. G.ДзидзарияА. Г.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

Дзидзария Александр Гудисович – кандидат медицинских наук, заведующий отделением

117997 Москва, ул. Профсоюзная, 86

dzidzariamd@gmail.comhttps://orcid.org/0000-0002-8665-3103FastovetsS. V.ФастовецС. В.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

Фастовец Сергей Владимирович – кандидат медицинских наук, научный сотрудник

117997 Москва, ул. Профсоюзная, 86

sega14@mail.ruKhoroshevskayaI. V.ХорошевскаяИ. В.
Russian Federation

86 Profsoyuznaya St., Moscow 117997

Хорошевская Ирина Викторовна – аспирант.

117997 Москва, ул. Профсоюзная, 86

clin_isl@mail.ruRussian Scientific Center of Roentgenradiology, Ministry of Health of RussiaФГБУ «Российский научный центр рентгенорадиологии» Минздрава России1305202319117242710202224032023https://oncourology.abvpress.ru/oncur/article/view/1632

Renal cell carcinoma is one of the most common malignant neoplasms of the genitourinary system. Along with smoking and hereditary syndromes associated with mutations in the Von Hippel-Lindau (VHL) gene, obesity is one of the main risk factors for the development of renal cell carcinoma. Emerging data indicate a causal relationship between obesity and development of renal cell carcinoma. In a large study within the framework of the Metabolic Syndrome and Cancer project, clinical data on blood pressure, body mass index, blood glucose, cholesterol and triglycerides were collected in 560,388 people. Individually, high glucose and triglyceride levels, as well as high body mass index and blood pressure, correlated with an increased risk of renal cell carcinoma in men, while only body mass index had a significant correlation in women.

Почечно-клеточный рак занимает одно из ведущих мест среди злокачественных новообразований мочеполовой системы. Наряду с курением и наследственными синдромами, связанными с мутациями в гене Von Hippel—Lindau (VHL), ожирение является одним из основополагающих факторов риска развития почечно-клеточного рака. Появляющиеся данные указывают на причинно-следственную связь ожирения с возникновением почечно-клеточного рака. В крупном исследовании в рамках проекта «Метаболический синдром и рак» были собраны клинические данные о кровяном давлении, индексе массы тела, уровнях глюкозы крови, холестерина и триглицеридов у 560 388 человек. Отдельно взятые высокие уровни глюкозы и триглицеридов, а также высокие индекс массы тела и артериальное давление коррелировали с повышенным риском развития почечно-клеточного рака у мужчин, в то время как только индекс массы тела имел значимую корреляцию у женщин.

kidney cancerrenal cell carcinomaobesityрак почкипочечно-клеточный ракожирение1. Arabsalmani M., Mohammadian-Hafshejani A., Ghoncheh M. et al. Incidence and mortality of kidney cancers, and human development index in Asia; a matter of concern. J Nephropathol 2017;6(1):30—42. DOI: 10.15171/jnp.2017.06Arabsalmani M., Mohammadian-Hafshejani A., Ghoncheh M. et al. Incidence and mortality of kidney cancers, and human development index in Asia; a matter of concern. J Nephropathol 2017;6(1):30—42. DOI: 10.15171/jnp.2017.062. Kabaria R., Klaassen Z., Terris M.K. Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis 2016;9:45-52. DOI: 10.2147/IJNRD.S75916Kabaria R., Klaassen Z., Terris M.K. Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis 2016;9:45-52. DOI: 10.2147/IJNRD.S759163. Chow W.H., Gridley G., Fraumeni J.FJr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000;343(18):1305-11. DOI: 10.1056/NEJM200011023431804Chow W.H., Gridley G., Fraumeni J.FJr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000;343(18):1305-11. DOI: 10.1056/NEJM2000110234318044. Johansson M., Carreras-Torres R., Scelo G. et al. The influence of obesity-related factors in the etiology of renal cell carcinoma - a mendelian randomization study. PLoS Med 2019;16(1):e1002724. DOI: 10.1371/journal.pmed.1002724Johansson M., Carreras-Torres R., Scelo G. et al. The influence of obesity-related factors in the etiology of renal cell carcinoma - a mendelian randomization study. PLoS Med 2019;16(1):e1002724. DOI: 10.1371/journal.pmed.10027245. Hakimi A.A., Furberg H., Zabor E.C. et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst 2013;105(24):1862-70. DOI: 10.1093/jnci/djt310Hakimi A.A., Furberg H., Zabor E.C. et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst 2013;105(24):1862-70. DOI: 10.1093/jnci/djt3106. Steffens S., Ringe K.I., Schroeer K. et al. Does overweight influence the prognosis of renal cell carcinoma? Results of a multicenter study. Int J Urol 2013;20(6):585-92. DOI: 10.1111/iju.12000Steffens S., Ringe K.I., Schroeer K. et al. Does overweight influence the prognosis of renal cell carcinoma? Results of a multicenter study. Int J Urol 2013;20(6):585-92. DOI: 10.1111/iju.120007. Budny A., Grochowski C., Kozlowski P. et al. Obesity as a tumour development triggering factor. Ann Agric Environ Med 2019;26(1):13-23. DOI: 10.26444/aaem/100664Budny A., Grochowski C., Kozlowski P. et al. Obesity as a tumour development triggering factor. Ann Agric Environ Med 2019;26(1):13-23. DOI: 10.26444/aaem/1006648. Allott E.H., Masko E.M., Freedland S.J. Obesity and prostate cancer: Weighing the evidence. Eur Urol 2013;63(5):800-9. DOI: 10.1016/j.eururo.2012.11.013Allott E.H., Masko E.M., Freedland S.J. Obesity and prostate cancer: Weighing the evidence. Eur Urol 2013;63(5):800-9. DOI: 10.1016/j.eururo.2012.11.0139. Santoni M., Cimadamore A., Massari F. et al. Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers. Cancers 2019;11(9):1225. DOI: 10.3390/cancers11091225Santoni M., Cimadamore A., Massari F. et al. Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers. Cancers 2019;11(9):1225. DOI: 10.3390/cancers1109122510. Massari F., Ciccarese C., Santoni M. et al. Metabolic phenotype of bladder cancer. Cancer Treat Rev 2016;45:46-57. DOI: 10.1016/j.ctrv.2016.03.005Massari F., Ciccarese C., Santoni M. et al. Metabolic phenotype of bladder cancer. Cancer Treat Rev 2016;45:46-57. DOI: 10.1016/j.ctrv.2016.03.00511. Stone T.W., McPherson M., Gail Darlington L. Obesity and cancer: existing and new hypotheses for a causal connection. EBioMedicine 2018;30:14-28. DOI: 10.1016/j.ebiom.2018.02.022Stone T.W., McPherson M., Gail Darlington L. Obesity and cancer: existing and new hypotheses for a causal connection. EBioMedicine 2018;30:14-28. DOI: 10.1016/j.ebiom.2018.02.02212. Ulrich C.M., Himbert C., Holowatyj A.N., Hursting S.D. Energy balance and gastrointestinal cancer: risk, interventions, outcomes and mechanisms. Nat Rev Gastroenterol Hepatol 2018;15(11):683-98. DOI: 10.1038/s41575-018-0053-2Ulrich C.M., Himbert C., Holowatyj A.N., Hursting S.D. Energy balance and gastrointestinal cancer: risk, interventions, outcomes and mechanisms. Nat Rev Gastroenterol Hepatol 2018;15(11):683-98. DOI: 10.1038/s41575-018-0053-213. Gao Q., Zheng J., Yao X., Peng B. Adiponectin inhibits VEGF-A in prostate cancer cells. Tumour Biol 2015;36(6):4287-92. DOI: 10.1007/s13277-015-3067-1Gao Q., Zheng J., Yao X., Peng B. Adiponectin inhibits VEGF-A in prostate cancer cells. Tumour Biol 2015;36(6):4287-92. DOI: 10.1007/s13277-015-3067-114. Lengyel E., Makowski L., DiGiovanni J., Kolonin M.G. Cancer as a matter of fat: the crosstalk between adipose tissue and tumors. Trends Cancer 2018;4(5):374-84. DOI: 10.1016/j.trecan.2018.03.004Lengyel E., Makowski L., DiGiovanni J., Kolonin M.G. Cancer as a matter of fat: the crosstalk between adipose tissue and tumors. Trends Cancer 2018;4(5):374-84. DOI: 10.1016/j.trecan.2018.03.00415. Romero I.L., Mukherjee A., Kenny H.A. et al. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res 2015;21(4):680-6. DOI: 10.1158/1078-0432.CCR-14-2198Romero I.L., Mukherjee A., Kenny H.A. et al. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res 2015;21(4):680-6. DOI: 10.1158/1078-0432.CCR-14-219816. Hotamisligil G.S., Bernlohr D.A. Metabolic functions of FABPs - mechanisms and therapeutic implications. Nat Rev Endocrinol 2015;11(10):592-605. DOI: 10.1038/nrendo.2015.122Hotamisligil G.S., Bernlohr D.A. Metabolic functions of FABPs - mechanisms and therapeutic implications. Nat Rev Endocrinol 2015;11(10):592-605. DOI: 10.1038/nrendo.2015.12217. Hancke K., Grubeck D., Hauser N. et al. Adipocyte fatty acidbinding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat 2010;119(2):367-77. DOI: 10.1007/s10549-009-0577-9Hancke K., Grubeck D., Hauser N. et al. Adipocyte fatty acidbinding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat 2010;119(2):367-77. DOI: 10.1007/s10549-009-0577-918. Hao J., Zhang Y., Yan X. et al. Circulating adipose fatty acid binding protein is a new link underlying obesity-associated breast/mammary tumor development. Cell Metab 2018;28(5):689-705. DOI: 10.1016/j.cmet.2018.07.006Hao J., Zhang Y., Yan X. et al. Circulating adipose fatty acid binding protein is a new link underlying obesity-associated breast/mammary tumor development. Cell Metab 2018;28(5):689-705. DOI: 10.1016/j.cmet.2018.07.00619. Greenhill C. A-FABP links obesity and breast cancer. Nat Rev Endocrinol 2018;14(10):566. DOI: 10.1038/s41574-018-0085-2Greenhill C. A-FABP links obesity and breast cancer. Nat Rev Endocrinol 2018;14(10):566. DOI: 10.1038/s41574-018-0085-220. Amin M.B., Greene F.L., Edge S.B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67(2):93-9. DOI: 10.3322/caac.21388Amin M.B., Greene F.L., Edge S.B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67(2):93-9. DOI: 10.3322/caac.2138821. Moch H., Humphrey P.A., Ulbright T.M., Reuter V.E. World Health Organization (WHO) Classification of Tumours of the Urinary System and Male Genital Organs. 4th edn. France, Lyon: IARC, 2016.Moch H., Humphrey P.A., Ulbright T.M., Reuter V.E. World Health Organization (WHO) Classification of Tumours of the Urinary System and Male Genital Organs. 4th edn. France, Lyon: IARC, 2016.22. Trpkov K., Grignon D.J., Bonsib S.M. et al. Handling and staging of renal cell carcinoma. The international society of urological pathology consensus (ISUP) conference recommendations. Am J Surg Pathol 2013;37(10):1505-17. DOI: 10.1097/PAS.0b013e31829a85d0Trpkov K., Grignon D.J., Bonsib S.M. et al. Handling and staging of renal cell carcinoma. The international society of urological pathology consensus (ISUP) conference recommendations. Am J Surg Pathol 2013;37(10):1505-17. DOI: 10.1097/PAS.0b013e31829a85d023. Samaratunga H., Gianduzzo T., Delahunt B. The ISUP system of staging, grading and classification of renal cell neoplasia. J Kidney Cancer VHL 2014;1(3):26-39. DOI: 10.15586/jkcvhl.2014.11Samaratunga H., Gianduzzo T., Delahunt B. The ISUP system of staging, grading and classification of renal cell neoplasia. J Kidney Cancer VHL 2014;1(3):26-39. DOI: 10.15586/jkcvhl.2014.1124. Cimadamore A., Palagonia E., Piccinni P. et al. Inguinal bladder hernia with lipomatosis of the bladder wall: a potential clinical pitfall for cancer. Urologia 2019;86(1):35-8. DOI: 10.1177/0391560319834494Cimadamore A., Palagonia E., Piccinni P. et al. Inguinal bladder hernia with lipomatosis of the bladder wall: a potential clinical pitfall for cancer. Urologia 2019;86(1):35-8. DOI: 10.1177/039156031983449425. Wahal S.P., Mardi K. Idiopathic renal replacement lipomatosis: a rare renal pseudo tumor. J Cancer Res Ther 2014;10(2):428-30. DOI: 10.4103/0973-1482.136680Wahal S.P., Mardi K. Idiopathic renal replacement lipomatosis: a rare renal pseudo tumor. J Cancer Res Ther 2014;10(2):428-30. DOI: 10.4103/0973-1482.13668026. Bonsib S.M. The renal sinus is the principal invasive pathway: a prospective study of 100 renal cell carcinomas. Am J Surg Pathol 2004;28(12):1594-600. DOI: 10.1097/00000478-200412000-00007Bonsib S.M. The renal sinus is the principal invasive pathway: a prospective study of 100 renal cell carcinomas. Am J Surg Pathol 2004;28(12):1594-600. DOI: 10.1097/00000478-200412000-0000727. Grignon D., Paner G.P. Renal cell carcinoma and the renal sinus. Adv Anat Pathol 2007;14(2):63-8. DOI: 10.1097/PAP.0b013e318032452eGrignon D., Paner G.P. Renal cell carcinoma and the renal sinus. Adv Anat Pathol 2007;14(2):63-8. DOI: 10.1097/PAP.0b013e318032452e28. Thompson R.H., Leibovich B.C., Cheville J.C. et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol 2005;174(4 Pt 1):1218-21. DOI: 10.1097/01.ju.0000173942.19990.40Thompson R.H., Leibovich B.C., Cheville J.C. et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol 2005;174(4 Pt 1):1218-21. DOI: 10.1097/01.ju.0000173942.19990.4029. Bonsib S.M., Gibson D., Mhoon M., Greene G.F. Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol.2000; 24(3):451-8. DOI: 10.1097/00000478-200003000-00015Bonsib S.M., Gibson D., Mhoon M., Greene G.F. Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol.2000; 24(3):451-8. DOI: 10.1097/00000478-200003000-0001530. Thompson R.H., Blute M.L., Krambeck A.E. et al. Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion. Am J Surg Pathol 2007;31(7):1089-93. DOI: 10.1097/PAS.0b013e31802fb4afThompson R.H., Blute M.L., Krambeck A.E. et al. Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion. Am J Surg Pathol 2007;31(7):1089-93. DOI: 10.1097/PAS.0b013e31802fb4af31. Bertini R., Roscigno M., Freschi M. et al. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases. J Urol 2009;181(1):2027-32. DOI: 10.1016/j.juro.2009.01.048Bertini R., Roscigno M., Freschi M. et al. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases. J Urol 2009;181(1):2027-32. DOI: 10.1016/j.juro.2009.01.04832. Delahunt B. Advances and controversies in grading and staging of renal cell carcinoma. Mod Pathol 2009;22(suppl 2):S24-36. DOI: 10.1038/modpathol.2008.183Delahunt B. Advances and controversies in grading and staging of renal cell carcinoma. Mod Pathol 2009;22(suppl 2):S24-36. DOI: 10.1038/modpathol.2008.18333. Margulis V., Tamboli P., Martin S.F. et al. Location of extrarenal tumor expression does not impact survival of patients with pT3a renal cell carcinoma. J Urol 2007;178:1878-82. DOI: 10.1016/j.juro.2007.07.011Margulis V., Tamboli P., Martin S.F. et al. Location of extrarenal tumor expression does not impact survival of patients with pT3a renal cell carcinoma. J Urol 2007;178:1878-82. DOI: 10.1016/j.juro.2007.07.01134. Chow W.H., McLaughlin J.K., Mandel J.S. et al. Obesity and risk of renal cell cancer. Cancer Epidemiol Prev Biomark 1996;5(1):17-21.Chow W.H., McLaughlin J.K., Mandel J.S. et al. Obesity and risk of renal cell cancer. Cancer Epidemiol Prev Biomark 1996;5(1):17-21.35. Setiawan V.W., Stram D.O., Nomura A.M. et al. Risk factors for renal cell cancer: The multiethnic cohort. Am J Epidemiol 2007;166(8):932-40. DOI: 10.1093/aje/kwm170Setiawan V.W., Stram D.O., Nomura A.M. et al. Risk factors for renal cell cancer: The multiethnic cohort. Am J Epidemiol 2007;166(8):932-40. DOI: 10.1093/aje/kwm17036. Adams K.F., Leitzmann M.F., Albanes D. et al. Body size and renal cell cancer incidence in a large US cohort study. Am J Epidemiol 2008;168(3):268-77. DOI: 10.1093/aje/kwn122Adams K.F., Leitzmann M.F., Albanes D. et al. Body size and renal cell cancer incidence in a large US cohort study. Am J Epidemiol 2008;168(3):268-77. DOI: 10.1093/aje/kwn12237. Dobbins M., Decorby K., Choi B.C. The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med 2013;2013:680536. DOI: 10.5402/2013/680536Dobbins M., Decorby K., Choi B.C. The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med 2013;2013:680536. DOI: 10.5402/2013/68053638. Samanic C., Chow W.H., Gridley G. et al. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 2006;17(7):901-9. DOI: 10.1007/s10552-006-0023-9Samanic C., Chow W.H., Gridley G. et al. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 2006;17(7):901-9. DOI: 10.1007/s10552-006-0023-939. Martini D.J., Liu Y., Shabto J.M. et al. Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI) ASCO Genitourin. Cancer 2019;37:e16068. DOI: 10.1200/JCO.2019.37.15_suppl.e16068Martini D.J., Liu Y., Shabto J.M. et al. Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI) ASCO Genitourin. Cancer 2019;37:e16068. DOI: 10.1200/JCO.2019.37.15_suppl.e1606840. Sidaway P. Kidney cancer: methylation of obesity-related genes is associated with prognosis. Nat Rev Urol 2017;14(8):452. DOI: 10.1038/nrurol.2017.94Sidaway P. Kidney cancer: methylation of obesity-related genes is associated with prognosis. Nat Rev Urol 2017;14(8):452. DOI: 10.1038/nrurol.2017.9441. Wang Q., Tu H., Zhu M. et al. Circulating obesity-driven biomarkers are associated with risk of clear cell renal cell carcinoma: a two-stage, case-control study. Carcinogenesis 2019;40(10):1191-7. DOI: 10.1093/carcin/bgz074Wang Q., Tu H., Zhu M. et al. Circulating obesity-driven biomarkers are associated with risk of clear cell renal cell carcinoma: a two-stage, case-control study. Carcinogenesis 2019;40(10):1191-7. DOI: 10.1093/carcin/bgz07442. Haggstrom C., Rapp K., Stocks T. et al. Metabolic factors associated with risk of renal cell carcinoma. PLoS One 2013;8(2):e57475. DOI: 10.1371/journal.pone.0057475Haggstrom C., Rapp K., Stocks T. et al. Metabolic factors associated with risk of renal cell carcinoma. PLoS One 2013;8(2):e57475. DOI: 10.1371/journal.pone.0057475